The U.S. Food and Drug Administration has approved Abeona Therapeutics' Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic skin disorder recessive dystrophic epidermolysis bullosa.

Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now ...

FDA approval of Zevaskyn was based on findings from two clinical studies. In a single-center, open-label, phase 1/2a study involving 38 chronic wounds in seven patients, a single surgical ...

Recessive dystrophic epidermolysis bullosa is a rare and serious condition. Zevaskyn is the first FDA-approved treatment for RDEB wounds with a single application. The FDA has approved Zevaskyn ...

Abeona Therapeutics Inc. today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah-skin’) (prademagene zamikeracel) gene-modified cellular ...

Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand ...

announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in adults and children with recessive dystrophic ...

Abeona Therapeutics transitions to a commercial-stage company with ZEVASKYN's FDA approval, QTC activation, and a PRV sale boosting operations toward ...